Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL; ConquerRSV Study Group. Wilson E, et al. Among authors: perez breva l. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. N Engl J Med. 2023. PMID: 38091530 Clinical Trial.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00002 booster cohorts study team. de Bruyn G, et al. EClinicalMedicine. 2023 Jul 22;62:102109. doi: 10.1016/j.eclinm.2023.102109. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37533419 Free PMC article.
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study.
Narejos Pérez S, Ramón Torrell JM, Põder A, Leroux-Roels I, Pérez-Breva L, Steenackers K, Vandermeulen C, Meisalu S, McNally D, Bowen JST, Heer A, Beltran Martinez A, Helman LL, Arora A, Feldman RG, Patel R, Shah A, Devadiga R, Damaso S, Matthews S, Pirçon JY, Luyts D. Narejos Pérez S, et al. Among authors: perez breva l. Open Forum Infect Dis. 2023 Mar 1;10(4):ofad111. doi: 10.1093/ofid/ofad111. eCollection 2023 Apr. Open Forum Infect Dis. 2023. PMID: 37065988 Free PMC article.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
Pérez-Breva L, Abad-Torreblanca R, Martínez-Beneito MÁ, Puig-Barberà J, Alemán-Sánchez S, Morant-Talamante N, Sastre-Cantón M, Vázquez-Moreno JA, Díez-Domingo J. Pérez-Breva L, et al. Vaccine. 2017 May 19;35(22):2949-2954. doi: 10.1016/j.vaccine.2017.04.022. Epub 2017 Apr 21. Vaccine. 2017. PMID: 28438407
Learning disease relationships from clinical drug trials.
Haslam B, Perez-Breva L. Haslam B, et al. Among authors: perez breva l. J Am Med Inform Assoc. 2017 Jan;24(1):13-23. doi: 10.1093/jamia/ocw003. Epub 2016 May 17. J Am Med Inform Assoc. 2017. PMID: 27189012 Free PMC article.
12 results